Cefepime (Maxipime, Bristol-Myers Squibb), a 4th generation cephalosporin was used in the postoperative treatment of 121 patients of Anesthesiology and Intensive Care Unit of Neurosurgical Clinics. The patients were divided into groups by the risk factor of pyoseptic complications. The results were estimated by the number and nature of the complications such as increasing liquor neutrophilic cytosis, systemic inflammations and others. The findings (increasing liquor neutrophilic cytosis only in 2 patients and endobronchitis in 4 patients) and good tolerance of cefepime (Maxipime) were in favour of its use in a dose of 1 g administered intravenously dropwise during initial narcosis and in 12 hours as an efficient agent for perioperative prophylaxis in neurosurgical patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Myoclonus: A Systematic Review.
Medicina (Kaunas)
January 2025
Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA.
: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).
View Article and Find Full Text PDFCorrelation Analysis Between Multi-Drug Resistance Phenotype and Virulence Factor Expression of Clinical .
Curr Issues Mol Biol
January 2025
School of Medicine, Foshan University, Foshan 528225, China.
(PA), as a common pathogen of nosocomial infections, has been experiencing an increasing rate of drug resistance with the widespread use and abuse of antimicrobial drugs. High-drug-resistance and high-virulence phenotypes are two distinctive features of the strong pathogenicity of multi-drug-resistant PA. Exploring the characterization of virulence factor expression and its relationship with the multi-drug resistance phenotype is essential to reduce the further development of resistance as well as a high standard of infection prevention and control.
View Article and Find Full Text PDFPiperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem.
J Chemother
January 2025
Department of Pharmacy, Kitasato University Hospital, Sagamihara, Kanagawa, Japan.
This retrospective study investigated whether piperacillin/tazobactam (PIPC/TAZ) monotherapy affects renal function compared to cefepime (CFPM) or meropenem (MEPM) monotherapy. Hospitalized patients who received PIPC/TAZ, CFPM, or MEPM monotherapy between April 2021 and December 2022 were enrolled in this study. We used inverse probability of treatment weighting (IPTW) to balance baseline characteristics and compare the incidence of acute kidney injury (AKI).
View Article and Find Full Text PDFMolecular detection of in bovine respiratory disease.
Vet Med (Praha)
December 2024
Department of Internal and Preventive Veterinary Medicine, College of Veterinary Medicine, University of Wasit, Wasit, Iraq.
Bovine respiratory disease (BRD) develops from complex interactions among environmental, host and pathogenic factors. This study aimed to phenotypically identify isolated from cattle with BRD and assess antimicrobial susceptibility and determining the molecular phylogeny of local strains. Between November 2023 and March 2024, nasal swabs were collected from 93 cattle with BRD, before culturing for phenotypic analysis, and performing the polymerase chain reaction (PCR) for molecular characterisation.
View Article and Find Full Text PDFA cross-sectional study on the prevalence of multidrug-resistant clinical isolates of Proteus species in Northern Iran.
J Infect Dev Ctries
December 2024
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Introduction: Multidrug-resistant (MDR) bacteria like Proteus species have led to more prolonged hospitalizations, fewer care choices, higher treatment costs, and even death. The present study aims to evaluate the prevalence of MDR Proteus species in clinical samples and to suggest the best therapeutic options for the MDR Proteus species.
Methodology: Clinical samples were collected randomly from five hospitals in Golestan Province, Iran, from February 2017 to July 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!